Tags · Evidence

SURMOUNT programme

Tirzepatide obesity trials.

24 topics 11 solved Synonyms: surmount-1 Group: Evidence

24 topics

Topic	Participants	Replies	Views	Activity
SURPASS-2 and the comparator dose question that will not go away — what changed since Compounds › Tirzepatide SURMOUNT programme tirzepatide effect size Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…	+2	6	5.5k	7h
What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what…	+16	20	23k	19h
Tirzepatide storage and stability: what is published versus what is assumed Compounds › Tirzepatide SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…	+17	21	17k	12d
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…	+62	68	2.6k	29d
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…	+109	122	3.6k	2mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…	+119	136	5.6k	2mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Compounds › Tirzepatide SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that…	+7	11	281	6mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Compounds › Tirzepatide SURMOUNT programme tirzepatide randomised trial Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Posting a small dataset on 2.5…	+12	16	11k	7mo
Reading SURMOUNT-1 without the press release Compounds › Tirzepatide SURMOUNT programme effect size randomised trial SURPASS programme Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. What changes if the standard account of reading SURMOUNT-1 without the press…	+103	121	7k	7mo
Why tirzepatide titration schedules have more steps than semaglutide's Compounds › Tirzepatide SURMOUNT programme SURPASS programme randomised trial tirzepatide Solved Wiki Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's I have spent a fortnight trying to pin tirzepatide titration schedules down…		4	8.4k	7mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Closed On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…	+85	90	13k	7mo
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Compounds › Tirzepatide SURMOUNT programme tirzepatide randomised trial effect size Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. Reading back through what has been written here about…	+4	8	14k	8mo
Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Asking about tirzepatide and nausea directly, because I…	+18	22	37k	8mo
[2026 update] Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…	+58	63	40k	9mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…	+122	136	48k	9mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Solved Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version A narrow question about GIP…	+48	52	609	10mo
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Reading back through what has been written here…		2	3.8k	10mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…		4	42k	11mo
Tirzepatide molecular mass and the charge states you would expect on ESI Compounds › Tirzepatide effect size SURPASS programme SURMOUNT programme randomised trial Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…	+36	40	44k	11mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Compounds › Tirzepatide tirzepatide SURPASS programme randomised trial effect size Solved Closed Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…	+150	163	22k	11mo
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…	+101	111	1.5k	18mo
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+130	137	11k	19mo
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide effect size SURMOUNT programme tirzepatide randomised trial Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…		2	23k	21mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →